Diabetes Drug Avandia Poses Higher Risks Than Actos

Washington (dbTechno) - A new study has found that the diabetes drug Avandia puts patients at a higher risk of death and heart failure than the rival diabetes drug Actos.

Avandia, from GlaxoSmithKline, has been under a lot of scrutiny as of late due to safety issues tied to it.

Researchers have found that older diabetics are better off taking the drug Actos from Takeda Pharmaceuticals, as it carries a lower risk of death and heart failure with it.

The drugs are in the same class and were put together for a head-to-head comparison.

This confirmed past research which revealed that the drug Avandia was more risky.

The study found no difference in the risk of heart attack and stroke.

They did find though that those in the Avandia group had higher risks of death and heart failure.

The study was led by Dr. Wolfgang Winkelmayer of the Brigham and Women’s Hospital in Boston and was published in the Archives of Internal Medicine.